Conference Coverage

Lidocaine Effective Against Pediatric Migraine


 

FROM AHS 2024

Important Research in an Understudied Population

Laine Greene, MD, who moderated the session, was asked for comment. “I think it’s an important study. Occipital nerve blocks have been used for a long period of time in management of migraine and other headache disorders. The quality of the evidence has always been brought into question, especially from payers, but also a very important aspect to this is that a lot of clinical trials over time have not specifically been done in children or adolescents, so any work that is done in that age category is significantly helpful to advancing therapeutics,” said Dr. Greene, associate professor of neurology at Mayo Clinic Arizona.

Dr. Szperka has consulted for AbbVie and Teva, and serves on data safety and monitoring boards for Eli Lilly and Upsher-Smith. She has been a principal investigator in trials sponsored by Abbvie, Amgen, Biohaven/Pfizer, Teva, and Theranica. Dr. Greene has no relevant financial disclosures.

Pages

Recommended Reading

Vaporized Cannabis for Acute Migraine Yields Rapid, Sustained Relief
MDedge Neurology
Lidocaine Nerve Block Effective for Severe, Refractory Migraine in Children
MDedge Neurology
Migraine Drug Reduces Rosacea Flushing, Erythema in Small Study
MDedge Neurology
TMS May Be a Good Alternative to ECT in Depression
MDedge Neurology
Proton Pump Inhibitors Tied to Migraine, Other Severe Headache Types
MDedge Neurology
Migraine Disability Nearly Doubled in US Between 2005 and 2018
MDedge Neurology
Greater Awareness Urged for Important, Overlooked Neuropsychiatric Symptoms of Lupus
MDedge Neurology
Interictal Burden, Disability, Allodynia Linked to Increased Likelihood of Seeking Migraine Care
MDedge Neurology
Measuring Cognition in Migraine, One Patient at a Time
MDedge Neurology
Potential Genes Identified for Post-Traumatic Headache
MDedge Neurology